Engage Bio developed a platform technology that enables non-viral delivery of DNA to cells. The acquisition is the latest in a series of Eli Lilly deals that expand the pharmaceutical company’s pipeline and capabilities in genetic medicines.
The post Eli Lilly Grows Again in Genetic Medicines, Buying Startup With a New Way to Deliver DNA appeared first on MedCity News.
